FOR AUTHORS
Search
Search Results
##search.searchResults.foundPlural##
-
Diagnostic and management practices for inherited fibrinogen disorders: a nationwide survey of Italian Hemophilia Treatment Centers
428PDF: 60HTML: 44Supplementary: 20Appendix: 34 -
Anticoagulation in obese patients: challenges and strategies
1834PDF: 264HTML: 196XML: 78 -
PO24 | Emicizumab prophylaxis and bleeding outcomes: a single center clinical experience A. Taglietti1, S. Ligia1, F. Paoletti1, R. Mormile1, E. Baldacci2, A. Chistolini1, C. Santoro1,2 | 1Hematology, Department of Translational and Precision Medicine, Sapienza University of Roma; 2Hematology, Azienda Ospedaliera Universitaria Policlinico Umberto I, Roma, Italy
477PDF: 0 -
PO86 | Emicizumab in patients with moderate hemophilia A and severe bleeding phenotype: single-center real-world experience A.L. Faccini, M. Biglietto, S. Sorella, E. Crisanti, M. Antonacci, R. Mormile, R. Ciciani, E. Baldacci, C. Santoro, S. Ligia | Hematology, Department of Translational and Precision Medicine Sapienza University of Roma, Italy
612PDF: 0 -
PO53 | PHASE 3 TRIAL EVALUATING THE EFFICACY AND SAFETY OF REGN7508CAT FOR PRIMARY PROPHYLAXIS OF CANCER-ASSOCIATED THROMBOSIS FOR PARTICIPANTS WITH SOLID TUMORS UNDERGOING CANCER TREATMENT (ROXI-CAT-I) J. Zwicker1, M. P. O’Brien2, M. Carrier3, J. Connors4, A. Falanga5, A. Manzano6, R. Mcbane7, Y.Y. Janjigian1, G. O’Kane8, M. Onisko2, J. Kaplan2, A.P. Kithcart2, D.E. Gutstein2, A. Khorana9, M. F. Walsh2 | 1Memorial Sloan Kettering Cancer Center, New York, USA; 2Regeneron Pharmaceuticals, Inc. , Tarrytown, NY, USA; 3University of Ottawa, Ottawa, ON, Canada; 4Harvard Medical School, Boston, MA, USA; 5Hospital Papa Giovanni XXIII, Bergamo, Italy; 6Hospital Universitario 12 de Octubre, Madrid, Spain; 7Mayo Clinic, Rochester, MN, USA; 8St. Vincent's University Hospital and School of Medicine, University College Dublin, Dublin, Ireland; 9James P. Wilmot Cancer Center and the Department of Medicine, University of Rochester, Rochester, NY, USA
64PDF: 16 -
PO82 | Retrospective application of the TH2 score in a multicenter cohort of ITP patients: a reliable predictive tool or a score in need of refinement? C. Giubbilei1, M. Defina2, S. Rosati3, M. Rocco3, A. Votto4, F. Simonetti5, F. Paoletti6, V. Carrai1 | 1Hematology Unit, AOU Careggi; 2Hematology unit AOU Senese; 3Hematology Unit Azienda Sanitaria Toscana Centro; 4Hematology Unit, AOU Pisana; 5Hematology Unit, Ospedale Versilia; 6Hematology Unit, Azienda Sanitaria Nord Ovest, Italy
449PDF: 0 -
CO07 | Real word management of anticoagulant therapy in brain metastasis: moving toward a multidisciplinary approach in complex cases E. Lotti1, C. Manneschi2, S. Fancelli2, F. Scolari1, F. Crudele1, D. Poli1, M. Berteotti1, D. Rossini3, S. Pillozzi2, L. Antonuzzo2,3, R. Marcucci1,3 | 1Disease Unit, Careggi University Hospital, Firenze; 2Oncology Unit, Careggi University Hospital, Firenze; <sup>3</sup>Department of Experimental and Clinical Biomedical Sciences, University of Firenze, Italy
510PDF: 0 -
PO25 | EVOLUTION OF ANTICOAGULANT STRATEGIES AND CLINICAL OUTCOMES IN CANCER-ASSOCIATED THROMBOSIS: A LONGITUDINAL ANALYSIS OF THE START2 REGISTRY ONCO-VTE M. Marchetti1|2, T. Zollner1|2, OC. Cretu1|2, A. Chistolini3, R. Pancani4, L. Puccetti5, P. Sivera6, W. Ageno7, G. Elmi8, V. Fregoni9, V. Tonelli10, E. Antonucci11, D. Poli11|12, A. Falanga1|2, L. Barcella1|2 | 1Hemostasis & Thrombosis Center, Department of Transfusion Medicine, Papa Giovanni XXIII Hospital, Bergamo Italy; 2ERN EuroBloodNet; 3Hematology Unit, Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy; 4Pulmonary Unit, Hospital of Siena, University of Siena, Siena, Italy; 5Hemostasis and Thrombosis Unit, Hospital of Siena, University of Siena, Siena, Italy; 6Haematology Unit, Ordine Mauriziano Hospital, Turin, Italy; 7Department of Medicine, University of Padua, Padua, Italy; 8Department of Medicine, Maggiore Hospital, Bologna, Italy; 9Department of Medicine, Sondalo Hospital, Sondalo, Italy; 10Angiology Unit, Sant'Eugenio Hospital, Rome, Italy; 11Arianna Anticoagulazione Foundation, Bologna, Italy; 12Department of Critical Care Medicine, Thrombosis Centre, Azienda Ospedaliera Universitaria Careggi, Firenze, Italy
66PDF: 19 -
PO50 | Treatment with BTK inhibitors in patients affected by chronic lymphocytic leukemia: safety and hemostasis L. Gurgoglione, C.A. Piro, I. Scortechini, I. Battilà, M.C. Merlo, A. R. Scortechini, S. Rupoli, A. Poloni | Hematology Unit, AOU delle Marche-Università Politecnica delle Marche, Italy
399PDF: 0 -
PO32 | ANTICOAGULANT THROMBOPROPHYLAXIS IN AGGRESSIVE LYMPHOMAS PATIENTS: PREDICTIVE THROMBOTIC RISK SCORES AND RISK FACTORS L. Gurgoglione1, G. Gini1, S. Rupoli1, A. Poloni1|2 | 1Hematology, AOU delle Marche, Ancona; 2Università Politecnica delle Marche, Ancona, Italy
56PDF: 17 -
PO12 | Characterisation and real word clinical data of HEM006, a newly formulated intranasal spray desmopressin (DDAVP) to address a global treatment gap G. De Giorgi1, A. Gringeri2, R. Franceschini1, A. Koganti3 | 1Hemorare Srl, Italy; 2Fondazione Charta, Milan, Italy; 3Quenya LLC, USA
435PDF: 0 -
PO31 | Comparative analysis of anticoagulant therapy in patients over 90 years old: vitamin K antagonists versus direct oral anticoagulants G. Sottilotta1, P. Arrigo2, S. Cuzzocrea1, D. Megalizzi1, F. Luise3 | 1UOSD Microcitemie, Emostasi e Trombosi, Grande Ospedale Metropolitano di Reggio Calabria; 2Associazione Italiana Pazienti Anticoagulati, Sezione di Reggio Calabria; 3Laboratorio Analisi. Grande Ospedale Metropolitano di Reggio Calabria, Italy
448PDF: 0 -
PO43 | Extended treatment with reduced dose of direct oral anticoagulants in patients with venous thromboembolism: a retrospective study A. Pannunzio1, E. Valeriani1, I.M. Palumbo1, D. Menichelli1, T. Brogi2, S. Marucci2, D. Pastori2, P. Pignatelli2 | 1Department of General Surgery and Surgical Specialty, Sapienza University of Roma; 2Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Roma, Italy
500PDF: 0 -
CO04 | Direct oral anticoagulants in antiphospholipid syndrome: a single center real-life experience A. Hoxha1, E. Campello1, F. Ahmad2, L. Spiezia1, P. Scarinzi1, G. Gobbo1, S. Gavasso1, F. Sartorello1, C. Simion1, E. Zanon1, P. Simioni1 | 1Internal Medicine Unit, Thrombotic and Haemorrhagic Centre, Department of Medicine - DIMED; 2Department of Statistical Sciences) University of Padova, Italy
608PDF: 0 -
Bleeding complications of oral anticoagulant therapy: from ISCOAT to the START Register A memory of Gualtiero Palareti
50PDF: 23 -
PO18 | THE THROMBO-INFLAMMATION AXIS AS PREDICTOR OF TOXICITY IN PATIENTS TREATED WITH CAR-T CELLS C. Fernández-Arias1, M. Marcos-Jubilar1, M. Panizo1, C. Vázquez-Puerta2, J.R. González-Porras2, M. Ibáñez1, A. Queralt1, M. Carrasco1, M.B. Villacrés1, C. Conde1, P. Elizalde1, S. Huerga1, A. Alfonso1, P. Rodríguez-Otero1, S. Villar1, M.A. Canales1, J. Rifón1, F. Prósper1, J.A. Páramo1, J. Orbe1, R. Lecumberri1 | 1Clínica Universidad de Navarra, Pamplona; 2Hospital Clínico Universitario de Salamanca, Salamanca, Spain
68PDF: 19 -
CO40 | The co-inheritance of two ITGB3 variants exerting additive detrimental effects on platelets leads to variant Glanzmann thrombasthenia N. Arndt1, E. Falcinelli1, A. Zamora-Cánovas2, A. Sánchez Fuentes2, A. Marín-Quilez2, I. Tano1, M.D.M. Nieto-Hernández3, J.M. Bastida4, J. Rivera2, P. Gresele1, L. Bury1 | 1Department of Medicine and Surgery, Section of Internal and Cardiovascular Medicine, University of Perugia, Italy; 2Servicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, Universidad de Murcia, IMIB-Pascual Parrilla, ISCIII-CIBERER, Murcia, Spain; 3Servicio de Hematología, Hospital Universitario de Jaen, Spain; 4Departamento de Hematología, Complejo Asistencial Universitario de Salamanca “CAUSA”, Instituto de Investigación Biomédica de Salamanca “IBSAL”, Centro de Investigación del Cáncer, IBMCC-CSIC, Universidad de Salamanca “USAL”, Salamanca, Spain
474PDF: 0 -
PO40 | RADAR, UK-MRA MYELOMA XV - COMPARING MRD-GUIDED TREATMENT ESCALATION AND DE-ESCALATION STRATEGIES IN PATIENTS WITH NEWLY DIAGNOSED MYELOMA SUITABLE FOR STEM CELL TRANSPLANTATION: THROMBOPROPHYLAXIS SUBGROUP STUDY PROTOCOL Z. Sayar, on behalf of the RADAR Investigators | Whittington Health NHS Trust and Royal Free Hospital, London, UK
64PDF: 15 -
PO35 | A MULTICENTRE AUDIT OF CURRENT TUMOUR THROMBOSIS MANAGEMENT IN THE UNITED KINGDOM A.A. Bhatti1, L. Tafesh1, A. Waton1, M. Thomas3, N. Prasannan3, A. Bhide3, R. Walsh3, T. Lucas3, K. White4, T. Bariana4, O. Tsiamita4, S. Soman4, P. Woolley5, I. Lacej5, K. Musgrave1|2 | 1Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK; 2Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK; 3University College London Hospitals NHS Foundation Trust, London, UK; 4Barts Health NHS Trust, London, UK; 5Imperial College Healthcare NHS Trust, London, UK
74PDF: 14 -
PO59 | Efficacy and safety of different anticoagulant treatment regimens for isolated internal jugular vein thrombosis: a case series A. Pannunzio1, E. Valeriani1, I.M. Palumbo1, S. Marucci2, D. Menichelli1, D. Pastori2, P. Pignatelli2 | 1Department of General Surgery and Surgical Specialty, Sapienza University of Roma; 2Department of Clinical, Internal Medicine, Anaesthesiological and Cardiovascular Sciences, Sapienza University of Roma, Italy
486PDF: 0 -
PO41 | VENOUS THROMBOEMBOLISM IN PERIPHERAL BLOOD STEM CELL COLLECTION. A SINGLE CENTER EXPERIENCE P. Holly1, J. Hudecek1, J. Chudej1, L. Valekova1, I. Plamenova1, E. Flochova1, R. Simonova1, J. Sokol1, J. Stasko1, M. Pietrzykova1|2, E. Vescecikova2 | 1Department of Hematology and Transfusion Medicine, University Hospital in Martin, Martin, Slovakia; 2National Transfusion Service, Martin, Slovakia
57PDF: 15 -
OC11 | COMPLEXITIES IN MANAGING ANTITHROMBOTIC THERAPY IN PATIENTS WITH CANCER APPROACHING END-OF-LIFE: A MIXED METHOD INTEGRATION USING JOINT DISPLAY ANALYSIS E. Baddeley1, L. Van’t Walderveen2, H. Enggaard3, M. Søgaard4, D. Abbel2, S. Cannegieter2, M. Edwards1, C. Font5, J. Goedegebuur2, F.A. Klok2, K.J. Lifford1, I. Mahé6, S.P. Mooijaart2, S.I.R. Noble1, M. Pearson7, K. Seddon1, S. Sivell1, S. Szmit8, S Trompet2, A.A. Højen4 | 1Cardiff University, Cardiff, UK; 2Leiden University Medical Center, Leiden, The Netherlands; 3Aalborg University Hospital, Aalborg, Denmark; 4Aalborg University and Aalborg University Hospital, Aalborg, Denmark; 5Hospital Clinic Barcelona, Barcelona, Spain; 6Paris Cité Université, Paris, France; 7Hull York Medical School, Hull, UK; 8Centre of Postgraduate Medical Education, Warsaw, Poland
53PDF: 20 -
OC03 | THROMBOEMBOLIC PREVALENCE IN MULTIPLE MYELOMA BEFORE AND AFTER THE INTRODUCTION OF DIRECT ORAL ANTICOAGULANTS: A LONGITUDINAL COHORT STUDY A. Ramírez1, A. Orozco2, A. Sánchez3, F. Villalpa1, S. Burgos2, G. Cesarman3, G. Rodríguez1, D. Vieyra2, J. Álvarez4, G.M. Flores3, S. González1, D. Martínez2, B. Cabello3, R. Espinoza3, O. Fernández3 | 1Myeloma-clinic Hematology service, Centro Médico Nacional La Raza, Instituto Mexicano del Seguro Social, México City, México; 2Myeloma-clinic Hematology service, Instituto Nacional de Nutrición Salvador Zubirán, México City, México; 3Myeloma-clinic Hematology service, Instituto Nacional de Cancerologçia, México City, Mexico; 4Centro Médico Nacional 20 de Noviembre, México City, Mexico
49PDF: 17 -
PO28 | Long term effectiveness and safety of venous thromboembolism with fondaparinux: data from the start registry I.M. Palumbo1, E. Valeriani1,2, A. Pannunzio1, S. Marucci3, D. Menichelli1, D. Pastori3,4, P. Pignatelli3 | 1Department of General Surgery and Surgical Specialty, Sapienza University of Roma; 2Department of Infectious Disease, Azienda Ospedaliero-Universitaria Policlinico Umberto I, Roma; 3Department of Clinical Internal, Anaesthesiologic and Cardiovascular Sciences, Sapienza University of Roma, Roma; 4IRCCS NeuRomad, Pozzilli, Italy
491PDF: 0 -
OC02 | INCIDENCE AND PREDICTORS OF ARTERIAL THROMBOSIS IN CANCER PATIENTS: RESULTS FROM THE PROSPECTIVE COMPASS-ARTERIAL CANCER ASSOCIATED THROMBOSIS (COMPASS-ARTECAT) STUDY M. Drakopoulou1, I. Diamandoulaki2, P. Baglaridis1, P. Las Casa3, P. Van Dreden4, K. Toutouzas1, G. Gerotziafas4|5 | 1First Department of Cardiology, School of Medicine, National and Kapodistrian University of Athens, Hippokration General Hospital, Athens, Greece; 2Department of Electrical and Computer Engineering, Aristotle University of Thessaloniki, Thessaloniki, Greece; 3Sorbonne University, INSERM UMR_S_938, CRSA, Research Department "Cancer, Vessels, Biology and Therapeutics" (CaVITE), Research Group "Cancer-Angiogenesis-Thrombosis and Haemostasis," Thrombosis Center, University Institute of Cancerology (UIC), Saint Antoine University Hospital Assistance Publique Hôpitaux de Paris (AP-HP) Paris France; 4Diagnostica Stago, clinical research, Gennevilliers, France; 5Center of Translational Research and Education, Department of Pathology and Laboratory Medicine, Loyola University Stritch School of Medicine, Maywood, Ill., USA
90PDF: 21
1 - 31 of 31 items
